Provided by Tiger Trade Technology Pte. Ltd.

InspireMD

0.7899
+0.01001.28%
Post-market: 0.80140.0115+1.46%16:10 EDT
Volume:31.96K
Turnover:24.99K
Market Cap:36.72M
PE:-1.22
High:0.8099
Open:0.8000
Low:0.7652
Close:0.7799
52wk High:2.57
52wk Low:0.6300
Shares:46.49M
Float Shares:25.94M
Volume Ratio:0.73
T/O Rate:0.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6464
EPS(LYR):-0.7584
ROE:-202.81%
ROA:-85.85%
PB:1.17
PE(LYR):-1.04

Loading ...

InspireMD Schedules Second-Quarter 2026 Results Conference Call and Webcast

Reuters
·
Aug 11

InspireMD to Announce Second Quarter 2026 Financial Results

GlobeNewswire
·
Aug 11

Insider Buyers At InspireMD Recover Some Losses, But Still Down US$161k

Simply Wall St.
·
Aug 08

InspireMD Grants 221,666 Restricted Shares to New Employee Under Inducement Plan

Reuters
·
Aug 08

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Aug 08

InspireMD Inc Expected to Post a Loss of 20 Cents a Share - Earnings Preview

Reuters
·
Jul 31

InspireMD Appoints Carotid Intervention Commercial Leader Kathleen Kennedy as Senior Vice President of Global Sales and Marketing

THOMSON REUTERS
·
Jul 31

InspireMD Eliminates Chief Commercial Officer Position

TIPRANKS
·
Jul 30

InspireMD Eliminates Chief Commercial Officer Role; Shane Gleason to Depart July 31

Reuters
·
Jul 30

InspireMD Receives Nasdaq Notice on Bid Price Compliance

TIPRANKS
·
Jul 24

Inspiremd Gets NASDAQ Notice for Failing $1 Minimum Bid Price Rule

Reuters
·
Jul 24

Inspiremd Director Raymond Cohen Resigns from Board, Effective July 1

Reuters
·
Jul 03

InspireMD grants 91,161 restricted shares to six new employees under inducement plan

Reuters
·
Jun 13

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 13

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire
·
Jun 13

InspireMD says FDA reviews PMA supplement for CGuard Prime 80 cm stent in TCAR use

Reuters
·
Jun 11

InspireMD reports zero major adverse events at 30 days in CGUARDIANS II TCAR study of CGuard Prime 80 cm stent

Reuters
·
Jun 11

InspireMD - No Deaths, Strokes, or Myocardial Infarctions Reported Within 30 Days in Cguardians Ii

THOMSON REUTERS
·
Jun 11

InspireMD - Cguardians Ii Trial Achieves 100% Acute Device Success Rate

THOMSON REUTERS
·
Jun 11

InspireMD Inc: Anticipates Potential Approval of Cguard Prime 80 Cm Stent Implant in Second Half of This Year

THOMSON REUTERS
·
Jun 11